AccuStem Sciences, Inc. Extends and Broadens Partnership with Instituto Europeo di Oncologia (IEO) Enabling its Strategic Approach to Address Unanswered Clinical Questions in Early Stage Breast Cancer
LONDON and PHOENIX, July 11, 2023 (GLOBE NEWSWIRE) — AccuStem Sciences, Inc. (OTCQB:ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, signs further agreement with the IEO, one of the most renowned comprehensive cancer centers in Europe. This important milestone will support the company’s strategic vision following positive results from transATAC study where StemPrintER assay outperformed the current market leader in risk of recurrence testing for women with early stage breast cancer.
Related news for (ACUT)
- AccuStem Sciences, Inc. and EmeritusDX Announce Partnership to Commercialize MSC Test for Lung Cancer Screening
- AccuStem Sciences, Inc. Signs Agreement to Access Blood Samples from Lung Cancer Screening Trial to Expedite MSC Commercialization Plan
- AccuStem Sciences to Offer its MSC Blood Test to Lung Cancer Screening Programs in the United States
- AccuStem Sciences, Inc. Announces Acquisition of Proprietary MSC Lung Cancer Screening Test
- AccuStem Sciences, Inc. and EmeritusDX Announce Joint Product Development Agreement and Strategic Partnership